121 related articles for article (PubMed ID: 24061331)
1. Remission of generalized anxiety disorder after 6 months of open-label treatment with venlafaxine XR.
Rickels K; Etemad B; Rynn MA; Lohoff FW; Mandos LA; Gallop R
Psychother Psychosom; 2013; 82(6):363-71. PubMed ID: 24061331
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
[TBL] [Abstract][Full Text] [Related]
3. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials.
Katz IR; Reynolds CF; Alexopoulos GS; Hackett D
J Am Geriatr Soc; 2002 Jan; 50(1):18-25. PubMed ID: 12028242
[TBL] [Abstract][Full Text] [Related]
4. Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study.
Nimatoudis I; Zissis NP; Kogeorgos J; Theodoropoulou S; Vidalis A; Kaprinis G
Int Clin Psychopharmacol; 2004 Nov; 19(6):331-6. PubMed ID: 15486518
[TBL] [Abstract][Full Text] [Related]
5. Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data.
Sheehan DV
J Clin Psychiatry; 2001; 62 Suppl 19():26-31. PubMed ID: 11577788
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.
Davidson JR; DuPont RL; Hedges D; Haskins JT
J Clin Psychiatry; 1999 Aug; 60(8):528-35. PubMed ID: 10485635
[TBL] [Abstract][Full Text] [Related]
7. Venlafaxine XR in the treatment of anxiety.
Hackett D
Acta Psychiatr Scand Suppl; 2000; (406):30-5. PubMed ID: 11131468
[TBL] [Abstract][Full Text] [Related]
8. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
Bose A; Korotzer A; Gommoll C; Li D
Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
[TBL] [Abstract][Full Text] [Related]
9. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
Silverstone PH; Ravindran A
J Clin Psychiatry; 1999 Jan; 60(1):22-8. PubMed ID: 10074873
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.
Rickels K; Pollack MH; Sheehan DV; Haskins JT
Am J Psychiatry; 2000 Jun; 157(6):968-74. PubMed ID: 10831478
[TBL] [Abstract][Full Text] [Related]
11. Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?
Baldwin DS; Schweizer E; Xu Y; Lyndon G
Eur Neuropsychopharmacol; 2012 Feb; 22(2):137-42. PubMed ID: 21839620
[TBL] [Abstract][Full Text] [Related]
12. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder.
Sheehan DV
J Clin Psychiatry; 1999; 60 Suppl 22():23-8. PubMed ID: 10634352
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of venlafaxine, extended release formulation, in the short-term and long-term treatment of generalized anxiety disorder: results of a survival analysis.
Montgomery SA; Mahé V; Haudiquet V; Hackett D
J Clin Psychopharmacol; 2002 Dec; 22(6):561-7. PubMed ID: 12454555
[TBL] [Abstract][Full Text] [Related]
14. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
Shelton C; Entsuah R; Padmanabhan SK; Vinall PE
Int Clin Psychopharmacol; 2005 Jul; 20(4):233-8. PubMed ID: 15933485
[TBL] [Abstract][Full Text] [Related]
15. Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of response.
Perugi G; Frare F; Toni C; Ruffolo G; Torti C
Neuropsychobiology; 2002; 46(3):145-9. PubMed ID: 12422062
[TBL] [Abstract][Full Text] [Related]
16. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
[TBL] [Abstract][Full Text] [Related]
17. Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies.
Pollack MH; Meoni P; Otto MW; Simon N; Hackett D
J Clin Psychopharmacol; 2003 Jun; 23(3):250-9. PubMed ID: 12826987
[TBL] [Abstract][Full Text] [Related]
18. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA;
J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
[TBL] [Abstract][Full Text] [Related]
19. Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release.
Rickels K; Etemad B; Khalid-Khan S; Lohoff FW; Rynn MA; Gallop RJ
Arch Gen Psychiatry; 2010 Dec; 67(12):1274-81. PubMed ID: 21135327
[TBL] [Abstract][Full Text] [Related]
20. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.
Simon JS; Aguiar LM; Kunz NR; Lei D
J Psychiatr Res; 2004; 38(3):249-57. PubMed ID: 15003430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
